Select a medication above to begin.
Covaryx HS
estrogens, esterified/ methyltestosterone
Black Box Warnings .
Endometrial Cancer Risk
estrogens incr. risk in postmenopausal women; rule out malignancy w/ endometrial sampling or other tests if undiagnosed persistent or recurrent abnormal vaginal bleeding; no evidence that 'natural' estrogens are more or less hazardous than 'synthetic' estrogens at equi-estrogenic doses
Cardiovascular and Other Risks
estrogens +/- progestins should not be used for cardiovascular dz or dementia prevention; incr. risk of MI, stroke, PE/DVT, and invasive breast CA in postmenopausal women 50-79 yo (WHI estrogen/progestin study regimen = conjugated estrogens 0.625 mg/day w/ medroxyprogesterone 2.5 mg/day x5y); incr. risk of probable dementia in postmenopausal women 65 yo and older (WHIMS estrogen/progestin substudy regimen = conjugated estrogens 0.625 mg/day w/ medroxyprogesterone 2.5 mg/day x4y); risk unknown in younger postmenopausal women; other doses or estrogen/progestin combos not studied, but assume similar risk; use lowest effective estrogen dose, shortest duration based on individual tx goals and risks
Adult Dosing .
Dosage forms: TAB: 0.625 mg/1.25 mg
vasomotor sx, mod-severe menopausal
- [1-2 tabs PO qd]
- Info: cycle 21 days on, 7 days off; use lowest effective estrogen dose, shortest effective tx duration; add progestin if intact uterus
renal dosing
- [see below]
- renal dz: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment/dz: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.